Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On GoalSeeking Alpha • 12/24/25
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 11/20/25
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 11/18/25
Why biotech and drug stocks are on the mend even though the rest of the market is hurtingMarket Watch • 11/18/25
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200%Investors Business Daily • 11/18/25
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025GlobeNewsWire • 10/30/25
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from hereCNBC • 10/30/25
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025GlobeNewsWire • 10/18/25
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerGlobeNewsWire • 09/02/25
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual MeetingGlobeNewsWire • 05/28/25
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?Zacks Investment Research • 05/21/25
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025GlobeNewsWire • 04/25/25
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a BetZacks Investment Research • 04/24/25
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)Zacks Investment Research • 04/10/25
Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable MarketSeeking Alpha • 04/08/25